Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Department of Surgery, University of California Irvine, Irvine, CA, USA.
Cancer Med. 2020 Sep;9(17):6256-6267. doi: 10.1002/cam4.3316. Epub 2020 Jul 20.
Despite evidence that liver resection improves survival in patients with colorectal cancer liver metastases (CRCLM) and may be potentially curative, there are no population-level data examining utilization and predictors of liver resection in the United States.
This is a population-based cross-sectional study. We abstracted data on patients with synchronous CRCLM using California Cancer Registry from 2000 to 2012 and linked the records to the Office of Statewide Health Planning Inpatient Database. Quantum Geographic Information System (QGIS) was used to map liver resection rates to California counties. Patient- and hospital-level predictors were determined using mixed-effects logistic regression.
Of the 24 828 patients diagnosed with stage-IV colorectal cancer, 16 382 (70%) had synchronous CRCLM. Overall liver resection rate for synchronous CRCLM was 10% (county resection rates ranging from 0% to 33%) with no improvement over time. There was no correlation between county incidence of synchronous CRCLM and rate of resection (R = .0005). On multivariable analysis, sociodemographic and treatment-initiating-facility characteristics were independently associated with receipt of liver resection after controlling for patient disease- and comorbidity-related factors. For instance, odds of liver resection decreased in patients with black race (OR 0.75 vs white) and Medicaid insurance (OR 0.62 vs private/PPO); but increased with initial treatment at NCI hospital (OR 1.69 vs Non-NCI hospital), or a high volume (10 + cases/year) (OR 1.40 vs low volume) liver surgery hospital.
In this population-based study, only 10% of patients with liver metastases underwent liver resection. Furthermore, the study identifies wide variations and significant population-level disparities in the utilization of liver resection for CRCLM in California.
尽管有证据表明肝切除术可提高结直肠癌肝转移(CRCLM)患者的生存率,并且可能具有潜在的治愈性,但在美国,尚无关于人群水平上肝切除术的应用和预测因素的相关数据。
这是一项基于人群的横断面研究。我们使用加利福尼亚癌症登记处从 2000 年到 2012 年期间提取了同时患有 CRCLM 的患者的数据,并将这些记录与全州卫生计划住院患者数据库进行了链接。量子地理信息系统(QGIS)被用于将肝切除术的比例映射到加利福尼亚县。使用混合效应逻辑回归确定患者和医院水平的预测因素。
在诊断为 IV 期结直肠癌的 24828 名患者中,有 16382 名(70%)患有同步 CRCLM。同步 CRCLM 的肝切除术总比例为 10%(县切除术比例范围为 0%至 33%),且随时间没有改善。县同步 CRCLM 的发病率与切除术比例之间没有相关性(R=0.0005)。在多变量分析中,社会人口统计学和治疗启动机构的特征与控制患者疾病和合并症相关因素后接受肝切除术独立相关。例如,与白人相比,黑人种族(比值比 0.75)和医疗补助保险(比值比 0.62)的患者接受肝切除术的可能性较低;但在 NCI 医院(比值比 1.69)或高容量(每年 10 例以上)(比值比 1.40)的肝脏手术医院进行初始治疗时,可能性更高。
在这项基于人群的研究中,只有 10%的肝转移患者接受了肝切除术。此外,该研究还发现,加利福尼亚州对 CRCLM 进行肝切除术的应用存在广泛差异和显著的人群水平差异。